Syndax Pharmaceuticals Inc (SNDX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Syndax Pharmaceuticals reported revenue of $172.4M, up 627.8% from $23.7M the year before. Net income was -$285.4M (a -165.6% net margin), or -$3.29 per diluted share. Operating margin was -158.4%. Operating activities generated -$323.0M of cash, leaving -$323.2M of free cash flow. At fiscal year end, Syndax Pharmaceuticals held $529.7M in total assets against $465.1M in total liabilities, including $134.9M of cash and equivalents.
Open the full interactive Syndax Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Syndax Pharmaceuticals Key Stats
| Share Price | $13.95 |
|---|---|
| Market Cap | $1.24B |
| Revenue YoY Growth | +627.8% |
| 52-Week Range | $13.11 – $25.15 |
| Shares Outstanding | 89.0 million (basic, 2026 Q2) |
Syndax Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $139.7M | $0 | $0 | $23.7M | $172.4M |
| Operating Income | -$71.4M | $26.2M | -$151.8M | -$230.0M | -$339.7M | -$273.1M |
| Pre-Tax Income | -$73.2M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.0M |
| Income Tax | $0 | $0 | — | — | — | $433,000 |
| Net Income | -$73.2M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.4M |
| Diluted EPS | -$1.87 | $0.46 | -$2.46 | -$2.98 | -$3.72 | -$3.29 |
Syndax Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $45.9M | $68.5M | $64.9M | $72.8M |
| Net Income | -$60.7M | -$68.0M | -$42.7M | -$49.4M |
| Diluted EPS | -$0.70 | -$0.79 | -$0.48 | -$0.55 |
Syndax Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $115.2M | $222.0M | $74.4M | $295.4M | $154.1M | $134.9M |
| Current Assets | $298.9M | $448.4M | $489.8M | $580.9M | $603.1M | $528.1M |
| Total Assets | $300.6M | $449.7M | $497.2M | $612.9M | $724.8M | $529.7M |
| Current Liabilities | $18.9M | $20.7M | $29.1M | $58.1M | $103.5M | $120.1M |
| Total Long-Term Debt | $20.1M | $19.9M | — | — | $669.4M | $350.0M |
| Total Liabilities | $48.4M | $41.3M | $29.8M | $58.7M | $436.7M | $465.1M |
| Shareholders' Equity | $252.2M | $408.4M | $467.4M | $554.2M | $288.1M | $64.6M |
Syndax Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$71.3M | $29.1M | -$133.7M | -$160.6M | -$274.9M | -$323.0M |
| Cash From Investing | -$142.5M | -$40.9M | -$186.2M | $117.6M | -$219.8M | $290.0M |
| Cash From Financing | $304.4M | $118.5M | $172.3M | $264.1M | $353.4M | $13.7M |
| Free Cash Flow | -$71.4M | $29.0M | -$133.7M | -$160.6M | — | -$323.2M |
Figures from Syndax Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Syndax Pharmaceuticals financials page for every line item.
Syndax Pharmaceuticals Company Profile
| Ticker | SNDX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001395937 |
Frequently Asked Questions
What was Syndax Pharmaceuticals' revenue in fiscal 2025?
Syndax Pharmaceuticals (SNDX) reported revenue of $172.4M for fiscal 2025.
What is Syndax Pharmaceuticals' annual revenue history?
Syndax Pharmaceuticals' annual revenue by fiscal year: 2020: $1.5M; 2021: $139.7M; 2022: $0; 2023: $0; 2024: $23.7M; 2025: $172.4M.
What was Syndax Pharmaceuticals' net income in fiscal 2025?
Syndax Pharmaceuticals reported net income of -$285.4M for fiscal 2025.
What was Syndax Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Syndax Pharmaceuticals' diluted EPS was -$3.29 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Syndax Pharmaceuticals generate in fiscal 2025?
Syndax Pharmaceuticals generated -$323.2M of free cash flow in fiscal 2025.
What was Syndax Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Syndax Pharmaceuticals reported revenue of $72.8M.
How much debt does Syndax Pharmaceuticals have?
Syndax Pharmaceuticals reported $350.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Syndax Pharmaceuticals are outstanding?
Syndax Pharmaceuticals reported a weighted average of 89.0 million basic shares outstanding in 2026 Q2.
What is Syndax Pharmaceuticals' market cap?
Based on its latest closing price, Syndax Pharmaceuticals (SNDX) has a market capitalization of about $1.24B.
When does Syndax Pharmaceuticals' fiscal year end?
Syndax Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Syndax Pharmaceuticals headquartered?
Syndax Pharmaceuticals lists its business address in New York, New York in its SEC filings.